.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR25_LamivudineAndDolutegravi.LamivudineAndDolutegravi .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR25_LamivudineAndDolutegravi.LamivudineAndDolutegravi| name: | LamivudineAndDolutegravir |
| ATC code: | J05AR25 | route: | oral |
| n-compartments | 1 |
Lamivudine and dolutegravir is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while dolutegravir is an integrase strand transfer inhibitor (INSTI). This combination is approved and widely used as a once-daily regimen in adults and adolescents for HIV therapy.
Pharmacokinetic parameters reported for healthy adult subjects receiving oral administration of the fixed dose combination (lamivudine 300 mg, dolutegravir 50 mg) as a single dose.
Singh, RP, et al., & Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development 10(9) 985–993. DOI:10.1002/cpdd.996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34265164
Chandasana, H, et al., & Pene Dumitrescu, T (2024). Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1. Antimicrobial agents and chemotherapy 68(5) e0150423–None. DOI:10.1128/aac.01504-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38587380
Singh, RP, et al., & Buchanan, AM (2022). Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children. The Pediatric infectious disease journal 41(3) 230–237. DOI:10.1097/INF.0000000000003366 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34817414